| Date | Company | Amount | Funding type | Investors | Therapeutic area | Type of Information |
|---|---|---|---|---|---|---|
| 2015-04-20 | Aduro Biotech (USA - CA) | $124.3 million | IPO | IPO | ||
| 2015-04-17 | Epizyme (USA - MA) | $130.7 million | IPO | IPO | ||
| 2015-04-16 | Autifony Therapeutics (UK) | £3.3 million | grant | Biomedical Catalyst Fund (UK) Innovate UK (UK) Medical Research Council (UK) | CNS diseases - Mental diseases | Grant |
| 2015-04-16 | Neurotrope BioScience (USA - NJ) | FRAXA Research Foundation (USA - MA) | Neurodegenerative diseases | Grant | ||
| 2015-04-15 | uniqure (The Netherlands) | $82.4 million (€76.5 million) | follow-on public offering | Genetic diseases - Rare diseases | Private placement | |
| 2015-04-15 | Myokardia (USA - CA) | $46 million | series B financing round | Casdin Capital (USA - NY) Cormorant Asset Management (USA - MA) Perceptive Life Sciences (USA - NY) BridgeBio (USA - CA) Sanofi (France) | Cardiovascular diseases | Series B financing round |
| 2015-04-13 | Angionetics, a newly-formed subsidiary of Taxus Cardium (USA - CA) | $ 3 million | equity investment | Shenzhen Qianhai Taxus (China) | Cardiovascular diseases | Fundraising |
| 2015-04-09 | Minoryx Therapeutics (Spain) | €2.4 million | financing round | la Caixa (Spain) Sanfilippo Foundation Switzerland (Switzerland) Healthequity (Spain) | Rare diseases | Financing round |
| 2015-04-09 | Antabio (France) | € 1 million | subvention | BpiFrance (France) | Infectious diseases | Subvention |
| 2015-04-09 | Neostem (USA - NY) | $1 million | grant | California Institute of Regenerative Medicine (CIRM) (USA - CA) | Ophtalmalogical diseases - Genetic diseases - Rare diseases | Grant |
| 2015-04-09 | Asceneuron (Switzerland) | $325,000 | grant | Alzheimer’s Drug Discovery Foundation (ADDF) (USA - NY) | Neurodegenerative diseases | Grant |
| 2015-04-08 | Prothena (Ireland) | capital increase | Capital increase | |||
| 2015-04-07 | Nabriva Therapeutics (Austria) | $120 million | series B financing round | Vivo Capital (USA - CA) OrbiMed (USA - NY) EcoR1 Capital (USA - CA) Tavistock Life Sciences (USA - CA) HBM Phase4 Partners (UK) Wellcome Trust (UK) GLSV (Germany) Novartis Venture Fund (Switzerland) | Infectious diseases | Series B financing round |
| 2015-04-07 | PhoreMost (UK) | £2.5 million ($3.8 million) | Financing round | Jonathan Milner (UK) Amadeus Capital (UK) Sunil Shah and Prashant Shah (O2H Ventures) (UK) Cambridge Enterprise (UK) Dr Chris Torrance (UK) | Technology - Services - Cancer - Oncology | Financing round |
| 2015-04-06 | Intercept Pharmaceuticals (USA - NY) | $366.8 million | financing round | Financing round | ||
| 2015-04-06 | Iteos Therapeutics (Belgium) ImaBiotech (France) | €0.8 million | grant | Walloon Region (Belgium) Bpifrance (France) | Grant | |
| 2015-04-01 | Tecrea (UK) Cobra Biologics (Sweden) | £112,291 | grant | Innovate UK (UK) | Technology - Services | Grant |
| 2015-03-31 | Atyr Pharma (USA - CA) | $76 Million | series E financing round | Sofinnova Ventures (France) undisclosed large institutional investor in the biotechnology industry, Federated Investors (USA - PA), Deerfield (USA - NY), Rock Springs Capital Management (USA - MD) EcoR1 Capital (USA - CA), Sphera Global Healthcare (Israel - USA - NY), two additional undisclosed institutional investors | Cancer - Oncology - Genetic diseases | Financing round |
| 2015-03-31 | Diamyd Medical (Sweden) | SEK 15 million | private placement | undisclosed group of international institutional investors, previously not shareholders in Diamyd Medical | Autoimmune diseases - Immunological diseases - Metabolic diseases | Private placement |
| 2015-03-31 | Tiziana Life Sciences (UK) | £2.55 million (€3.48 million) | private placement | Cancer - Oncology | Private placement |
